cancers,

Enoblituzumab, a monoclonal antibody drug works by binding to a protein called B7-H3 that is overexpressed on prostate cancer cells and believed to impede the immune system’s ability to attack cancer cells. The new drug is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body, according to […] More